Literature DB >> 1634078

Endogenous opioids accumulate in plasma in a rat model of acute cholestasis.

M G Swain1, R B Rothman, H Xu, J Vergalla, N V Bergasa, E A Jones.   

Abstract

To obtain data on the degree to which the opioid system is changed in cholestasis, endogenous opioid activity in plasma of rats with acute cholestasis was determined 5 days after bile duct resection. Total plasma opioid activity was determined using a radioreceptor technique that measured the displacement of the opiate receptor ligand [3H]-DAMGO from lysed synaptosomal fractions of normal rat brain. Plasma total opioid activity was threefold greater in bile duct-resected rats than in sham-operated and unoperated controls (P less than or equal to 0.05). Plasma levels of the individual endogenous opioid, methionine-enkephalin, were determined using a sensitive radioimmunoassay, and the specificity of the assay was confirmed using high-performance liquid chromatography. In cholestatic rats, plasma methionine-enkephalin levels were more than six-fold greater than in sham-operated controls (P less than or equal to 0.001) and more than 17-fold greater than in unoperated controls (P less than or equal to 0.001). However, plasma methionine-enkephalin levels accounted for less than 5% of total plasma opioid activity after bile duct resection. Plasma methionine-enkephalin levels in both cholestatic plasma and plasma from sham-operated animals were stable when incubated in vitro despite the presence of undiminished activity of the major enkephalin-degrading enzymes. Thus, protection of methionine-enkephalin from degradation may be a factor contributing to the elevated plasma levels of methionine-enkephalin found in cholestasis. The magnitude of the increase in plasma endogenous opioid activity in bile duct-resected rats provides support for the hypothesis that endogenous opioids contribute to the pathophysiology of cholestasis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1634078     DOI: 10.1016/0016-5085(92)90857-u

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  20 in total

Review 1.  Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy.

Authors:  Thomas Pusl; Ulrich Beuers
Journal:  Clin Rev Allergy Immunol       Date:  2005-04       Impact factor: 8.667

Review 2.  Jaundice associated pruritis: a review of pathophysiology and treatment.

Authors:  Ramez Bassari; Jonathan B Koea
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

3.  Why do cholestatic patients itch?

Authors:  E A Jones; N V Bergasa
Journal:  Gut       Date:  1996-05       Impact factor: 23.059

4.  Pharmacokinetics and dialysability of naltrexone in patients undergoing hemodialysis.

Authors:  Nicolas K Kambia; Thierry Dine; Pascal Odou; Salmane Bah; Raymond Azar; Bernard Gressier; Thérèse Dupin-Spriet; Michel Luyckx; Claude Brunet
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2004 Oct-Dec       Impact factor: 2.441

5.  The TGR5 receptor mediates bile acid-induced itch and analgesia.

Authors:  Farzad Alemi; Edwin Kwon; Daniel P Poole; TinaMarie Lieu; Victoria Lyo; Fiore Cattaruzza; Ferda Cevikbas; Martin Steinhoff; Romina Nassini; Serena Materazzi; Raquel Guerrero-Alba; Eduardo Valdez-Morales; Graeme S Cottrell; Kristina Schoonjans; Pierangelo Geppetti; Stephen J Vanner; Nigel W Bunnett; Carlos U Corvera
Journal:  J Clin Invest       Date:  2013-03-25       Impact factor: 14.808

Review 6.  Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics.

Authors:  Mellar Davis
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 7.  Clinical features and management of primary biliary cirrhosis.

Authors:  Andrea Crosignani; Pier-Maria Battezzati; Pietro Invernizzi; Carlo Selmi; Elena Prina; Mauro Podda
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

8.  Suppression of hypothalamic-pituitary-adrenal axis responsiveness to stress in a rat model of acute cholestasis.

Authors:  M G Swain; V Patchev; J Vergalla; G Chrousos; E A Jones
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

Review 9.  Drug treatment of pruritus in liver diseases.

Authors:  Vinod S Hegade; Stuart F W Kendrick; David E J Jones
Journal:  Clin Med (Lond)       Date:  2015-08       Impact factor: 2.659

Review 10.  Pathogenesis and treatment of pruritus in cholestasis.

Authors:  Andreas E Kremer; Ulrich Beuers; Ronald P J Oude-Elferink; Thomas Pusl
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.